

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/072045 A3

(51) International Patent Classification⁷: **C07K 19/00**,
A61K 38/26, 38/22, A61P 3/10, C07K 14/605, 14/595

(74) Agents: **KURDYDYK, Linda** et al.; McCarthy Tetrault,
Suite 4700, P.O. Box 48, 66 Wellington Street West,
Toronto Dominion Bank Tower (CA).

(21) International Application Number:
PCT/CA2005/000099

(22) International Filing Date: 28 January 2005 (28.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/540,803 30 January 2004 (30.01.2004) US
60/540,804 30 January 2004 (30.01.2004) US

(71) Applicant (for all designated States except US):
WARATAH PHARMACEUTICALS, INC. [CA/CA];
415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7
(CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CRUZ, Antonio**
[CA/CA]; 89 Dunloe Road, Toronto, Ontario M5P 2T7
(CA). **PASTRAK, Aleksandra** [CA/CA]; 120 Glenvale
Boulevard, Toronto, Ontario M4G 2V9 (CA). **HEW, Yin**
[SG/SG]; c/o Transition Therapeutics Inc., 415 Yonge
Street, Suite 1003, Toronto, Ontario, Canada M5B 2E7
(SG).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
27 October 2005

[Continued on next page]

(54) Title: THE COMBINED USE OF GLP-1 AGONISTS AND GASTRIN FOR REGULATING BLOOD GLUCOSE LEVELS



(57) Abstract: The invention relates to compositions, conjugates, and methods for the prevention and/or treatment of a condition and/or disease comprising a therapeutically effective amount of a GLP-1 agonist and a gastrin compound. The combination of a GLP-1 agonist and a gastrin compound provides beneficial effects, in particular sustained beneficial effects, in the prevention and/or treatment of conditions and/or diseases for which either a GLP-1 agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, obesity, metabolic syndrome and related diseases and disorders. Combinations of a GLP-1 agonist and a gastrin compound can be selected

to provide unexpectedly additive effects or synergistic effects.

WO 2005/072045 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.